Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

24.38 +1.20 (+5.18%)
Streaming Delayed Price Updated: 12:03 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
From Arcus Biosciences
Via Business Wire
News headline image
Navigating 5 Analyst Ratings For Arcus Biosciences ↗
 
Via Benzinga
News headline image
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Arcus Biosciences
Via Business Wire
News headline image
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies ↗
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response... 
Via Benzinga
News headline image
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024 ↗
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Recap: Arcus Biosciences Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 21, 2024 ↗
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
News headline image
Preview: Arcus Biosciences's Earnings ↗
 
Via Benzinga
News headline image
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.